Half Year 2025 Formycon AG Earnings Call Transcript
Key Points
- Formycon AG (XTER:FYB) reconfirmed its full-year guidance for revenue and EBITDA, supported by a successful Eurobond placement.
- The company achieved a significant milestone with the pembrolizumab Phase III waiver, allowing faster and more cost-effective biosimilar development.
- Formycon AG expanded its geographic reach with approvals and partnerships in Brazil and Sub-Saharan Africa, enhancing its market diversification strategy.
- The launch of FYB202/Otulfi in the US, key European markets, and Canada, along with the introduction of Fymskina in Germany, indicates strong market penetration.
- The company successfully issued a Nordic bond, raising EUR 70 million to further develop its product pipeline and enhance financial flexibility.
- Revenues for H1 2025 were lower compared to H1 2024, reflecting a backloaded revenue structure for the year.
- The company faced reduced contributions from its joint venture, Bioeq, due to Sandoz pausing US activities and price pressures.
- FYB201 royalties decreased as a result of paused marketing in the US, impacting overall revenue.
- The financial performance is heavily reliant on expected licensing deals and revenue generation in Q4 2025, creating uncertainty.
- The company is navigating multiple litigation and court proceedings for FYB203, which could affect the timing of market launches.
Good afternoon, good morning, and warm welcome also from my side.
We appreciate, of course, as always, your attendance and the interest into Formycon's H1 earnings call. Earlier today, as you might have read, we issued a press release with detailed insights on our midyear performance. And in a nutshell, I'm very pleased to reconfirm the full-year guidance for revenue and EBITDA, while working capital cash is boosted by our recent highly successful Eurobond placement.
We are also looking back at a period with very strong operational achievements across many areas. And particularly, I want to mention our pembrolizumab Phase III waiver, which is putting us in a very strong competitive lead position and opens up manyfold opportunities for this attractive asset and beyond because this breakthrough will allow Formycon to develop biosimilars faster and at lower cost. The financial numbers of the first half year are still indicating that we are at the starting point of the commercial ramp up. They are in line
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
